Emory Vaccine Center scientists discovered the role of the PD-1 protein in inhibiting the immune response to chronic viral infections, which paved the way for cancer immunotherapy.

Emory's biotechnology company DRIVE: Drug Innovation Ventures at Emory, identifies promising discoveries and licenses them through the Emory Institute for Drug Development, housed in a 12,000 square foot facility on the Emory campus. DRIVE is focused on drugs to treat globally challenging infections such as Dengue, Chikungunya, Rift Valley fever, respiratory syncytial virus, and equine encephalitis.